Company news
Axim Biotechnologies, Inc. (OTC:AXIM) news
Axim Biotechnologies, Inc. news releases on 6ix. Latest, Sep 10, 2019: Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol…
Press releases — page 3
Axim® Biotechnologies Begins Manufacturing Cannabinoid-Based Gum With Dronabinol for Use in Upcoming Pre-Clinical Studies
September 10, 2019
New U.S. Patent Allowance Granted To Axim® Biotechnologies For Anti-Microbial Compositions Comprising Cannabinoids
August 8, 2019
AXIM® Biotechnologies Featured in Bloomberg Law for Robust Cannabinoid-Based Patent Portfolio
August 6, 2019
AXIM® Biotechnologies Launches AXIM® Wellness Division Focused on Cannabinoid-Based Nutraceutical Products and Announces New Product Pipeline
July 30, 2019
AXIM® Biotechnologies Receives Seventh Private Label Gum Purchase Order Pushing Orders to Nearly $900,000 for Last Five Months
July 11, 2019
AXIM® Biotechnologies Signs Licensing Agreement With Leading Gum Distributor to Expand Nutraceutical Division
July 9, 2019
Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies, Inc.'s Cannabinoid Oral Care Products Registered For Use In Clinical Trials Through Australian Healthcare Partner
June 26, 2019
AXIM® Biotechnologies Signs Supply Agreement to Register Cannabinoid Oral Care Products in Clinical Trials for Gingivitis and Gum Disease
June 25, 2019
FOX Business Features Opinion Article Authored by AXIM Biotechnologies, Inc. CEO on Why Legal CBD is Good for Consumers and the Economy
June 5, 2019
AXIM® Biotechnologies, Inc. Signs Cannabinoid Product Supply Agreement with Healthcare Company for Clinical Trials on Treatment of Periodontitis
June 3, 2019
Cannastocks2019 Investor Conference & Webinar Now Available for On-Demand Viewing
May 17, 2019
AXIM® Biotechnologies Announces Additional Purchase Order for Nutraceutical Product With Leading Direct Selling Company
May 15, 2019
Cannastocks2019 Live-Stream Investor Conference & Webinar May 15th
May 14, 2019
Medical Marijuana, Inc. Major Investment Company Axim® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms
May 14, 2019
AXIM® Biotechnologies to Present at Cannastocks 2019 Q1 Conference
May 14, 2019
AXIM® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms
May 9, 2019
AXIM® Biotechnologies, Inc. Nutraceutical Division Receives Purchase Order for 50,000 Boxes of the Company’s Proprietary CBD-Based Chewing Gum
April 23, 2019
AXIM® Biotechnologies, Inc. Announces Attendance and Presentation by Chief Technology Officer Lekhram Changoer at Kannaway® “Believe” National Convention
April 12, 2019
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Enters Services Agreement with CRO to Begin Clinical Studies on Dronabinol and CBD Chewing Gums
April 10, 2019
AXIM® Biotech Enters Services Agreement With CRO to Begin Clinical Studies On Dronabinol and CBD Chewing Gums
April 9, 2019
AXIM® Biotechnologies, Inc. Appoints Mauricio Javier Gatto-Bellora to Company’s Board of Directors
April 4, 2019
Medical Marijuana, Inc. Portfolio Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Topical Cream Containing Cannabinoids
March 27, 2019
Axim® Biotechnologies Receives New U.S. Patent Issuance for Topical Cream Containing Cannabinoids
March 19, 2019
AXIM® Biotechnologies Announces Successful Microencapsulation of Cannabinoids Into Proprietary Chewing Gum Delivery Mechanism for Clinical Trials
February 26, 2019
Medical Marijuana, Inc. Subsidiary Kannaway® Places Significant Initial Purchase Order for Major Investment Company AXIM® Biotechnologies CBD Chewing Gum
February 14, 2019
AXIM® Biotechnologies Announces Significant Initial Purchase Order for Nutraceutical Product With Leading Direct Selling Company
February 12, 2019
New U.S. Patent Issuance Granted to AXIM® Biotechnologies for Oral Care Composition Containing Cannabinoids
January 29, 2019
AXIM® Biotechnologies Launches New Website and Management Presentation To Outline Strategic Business Initiatives
January 15, 2019
AXIM® Biotechnologies Appoints New Chief Executive Officer
January 8, 2019
New U.S. Patent Allowance Granted to AXIM® Biotechnologies for Suppository Formulations Comprised of Cannabinoids
October 23, 2018
Axim® Biotechnologies Earns GMP License From Dutch Ministry of Health to Produce Cannabinoid-Based Pharmaceutical Products
October 16, 2018
AXIM® Biotechnologies Signs LOI for Distribution of Products Throughout Australia and New Zealand
September 13, 2018
AXIM® Biotechnologies Enters Canadian Market Through New Exclusive Distribution and License Agreement With Revive Therapeutics
August 27, 2018
AXIM® Biotechnologies to Present at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
August 15, 2018
Axim® Biotechnologies Announces Positive Results From Stability And Dissolution Tests On Medchew Rx Showing Greater Than 90% Availability
August 7, 2018
AXIM® Biotechnologies to Present at 28th Annual International Cannabinoid Research Society Symposium in The Netherlands
June 28, 2018
New U.S. Patent Allowance Granted to AXIM® Biotechnologies for Extraction and Purification of Delta-9-THC For Use in MedChew RX Clinical Program
June 19, 2018
AXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramco
May 15, 2018
AXIM Biotech Secures Additional Funding to Advance Cannabidnoid-Based Clinical Development Program for Multiple Indications
April 23, 2018
AXIM Biotech Files Patent Application on Product Formulation Comprised of Cannabinoids With Anti-Bacterial and Anti-Fungal Activities
April 18, 2018
AXIM Biotech Reaches Preliminary Agreement for Distribution of CanChew and MedChew Products Throughout South Korea
April 3, 2018
AXIM Biotech to Attend BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference in New York
March 21, 2018
AXIM Biotechnologies Reports Year End 2017 Results
March 19, 2018
Medical Marijuana, Inc. Major Investment AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules
February 28, 2018
AXIM Biotech Announces First-Ever Successful Achievement of Proprietary cGMP Extraction and Manufacturing Methods for Pure Cannabinoid Molecules
February 27, 2018
CBS News Covers AXIM Biotech’s Patent Filing for Controlled-Release Chewing Gum to Provide Treatment for Opioid Addiction
February 21, 2018
AXIM Biotech Enters Into Distribution Agreement for Proprietary Cannabinoid-Based Nutraceutical Chewing Gum Product CanChew+ Throughout Thailand
February 6, 2018
AXIM Biotech Announces Successful Completion of Exploratory Meeting with the Dutch Medicines Evaluation Board on MedChew Rx Program for Treatment of Pain and Spasticity in MS Patients
January 23, 2018
AXIM Biotech Attends Biotech Showcase Conference in San Francisco
January 4, 2018
AXIM Biotech Advances Programs Through Traditional Biotech Pathways, Positive Meeting with FDA -- SECFilings.com
December 13, 2017